Literature DB >> 21934851

Plasmonic chiral contrast agents for optical coherence tomography: numerical study.

Kalpesh B Mehta1, Nanguang Chen.   

Abstract

Optical coherence tomography (OCT) is a widely used morphological imaging modality. Various contrast agents, which change localized optical properties, are used to extend the applicability of OCT, where intrinsic contrast is not sufficient. In this paper we propose the use of a dual-rod gold nano-structure as a polarization sensitive contrast agent. Using numerical simulation, we demonstrated that the proposed structure has tunable chiral response. Enhanced cross-section due to Plasmon resonance in gold nanoparticles, along with the chiral behavior can provide enhanced detection sensitivity. The proposed contrast agents may extend the applicability of OCT to the problems that require the molecular contrast with enhanced sensitivity.

Mesh:

Substances:

Year:  2011        PMID: 21934851     DOI: 10.1364/OE.19.014903

Source DB:  PubMed          Journal:  Opt Express        ISSN: 1094-4087            Impact factor:   3.894


  4 in total

1.  Dark-field circular depolarization optical coherence microscopy.

Authors:  Kalpesh Mehta; Pengfei Zhang; Eugenia Li Ling Yeo; James Chen Yong Kah; Nanguang Chen
Journal:  Biomed Opt Express       Date:  2013-08-19       Impact factor: 3.732

2.  Plasmonic Nanoparticles: Advanced Researches (II).

Authors:  Hyejin Chang; Sang Hun Lee; Jaehi Kim; Won-Yeop Rho; Xuan-Hung Pham; Dae Hong Jeong; Bong-Hyun Jun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Magnetic and Plasmonic Contrast Agents in Optical Coherence Tomography.

Authors:  Amy L Oldenburg; Richard L Blackmon; Justin M Sierchio
Journal:  IEEE J Sel Top Quantum Electron       Date:  2016-04-12       Impact factor: 4.544

4.  Imaging single chiral nanoparticles in turbid media using circular-polarization optical coherence microscopy.

Authors:  Pengfei Zhang; Kalpesh Mehta; Shakil Rehman; Nanguang Chen
Journal:  Sci Rep       Date:  2014-05-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.